Literature DB >> 28408437

The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.

Francesca R Dejure1, Nadine Royla2, Steffi Herold1, Jacqueline Kalb1, Susanne Walz3, Carsten P Ade1, Guido Mastrobuoni2, Jens T Vanselow4, Andreas Schlosser4, Elmar Wolf5, Stefan Kempa6, Martin Eilers7.   

Abstract

Deregulated expression of MYC enhances glutamine utilization and renders cell survival dependent on glutamine, inducing "glutamine addiction". Surprisingly, colon cancer cells that express high levels of MYC due to WNT pathway mutations are not glutamine-addicted but undergo a reversible cell cycle arrest upon glutamine deprivation. We show here that glutamine deprivation suppresses translation of endogenous MYC via the 3'-UTR of the MYC mRNA, enabling escape from apoptosis. This regulation is mediated by glutamine-dependent changes in adenosine-nucleotide levels. Glutamine deprivation causes a global reduction in promoter association of RNA polymerase II (RNAPII) and slows transcriptional elongation. While activation of MYC restores binding of MYC and RNAPII function on most promoters, restoration of elongation is imperfect and activation of MYC in the absence of glutamine causes stalling of RNAPII on multiple genes, correlating with R-loop formation. Stalling of RNAPII and R-loop formation can cause DNA damage, arguing that the MYC 3'-UTR is critical for maintaining genome stability when ribonucleotide levels are low.
© 2017 The Authors.

Entities:  

Keywords:  zzm321990MYCzzm321990; 3′‐UTR; RNA polymerase II; glutamine

Mesh:

Substances:

Year:  2017        PMID: 28408437      PMCID: PMC5494468          DOI: 10.15252/embj.201796662

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  73 in total

Review 1.  Reflecting on 25 years with MYC.

Authors:  Natalie Meyer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

2.  Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.

Authors:  Shripad V Bhagwat; Prafulla C Gokhale; Andrew P Crew; Andy Cooke; Yan Yao; Christine Mantis; Jennifer Kahler; Jennifer Workman; Mark Bittner; Lorina Dudkin; David M Epstein; Neil W Gibson; Robert Wild; Lee D Arnold; Peter J Houghton; Jonathan A Pachter
Journal:  Mol Cancer Ther       Date:  2011-06-14       Impact factor: 6.261

3.  c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.

Authors:  Zuqin Nie; Gangqing Hu; Gang Wei; Kairong Cui; Arito Yamane; Wolfgang Resch; Ruoning Wang; Douglas R Green; Lino Tessarollo; Rafael Casellas; Keji Zhao; David Levens
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

4.  Plasma amino acid levels in diabetic ketoacidosis.

Authors:  P Felig; E Marliss; J L Ohman; C F Cahill
Journal:  Diabetes       Date:  1970-10       Impact factor: 9.461

5.  Negative autoregulation of c-myc transcription.

Authors:  L J Penn; M W Brooks; E M Laufer; H Land
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

6.  ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.

Authors:  Guoliang Qing; Bo Li; Annette Vu; Nicolas Skuli; Zandra E Walton; Xueyuan Liu; Patrick A Mayes; David R Wise; Craig B Thompson; John M Maris; Michael D Hogarty; M Celeste Simon
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

7.  p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.

Authors:  N R Christoffersen; R Shalgi; L B Frankel; E Leucci; M Lees; M Klausen; Y Pilpel; F C Nielsen; M Oren; A H Lund
Journal:  Cell Death Differ       Date:  2009-08-21       Impact factor: 15.828

8.  The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo.

Authors:  Maurice Reimann; Christoph Loddenkemper; Cornelia Rudolph; Ines Schildhauer; Bianca Teichmann; Harald Stein; Brigitte Schlegelberger; Bernd Dörken; Clemens A Schmitt
Journal:  Blood       Date:  2007-06-11       Impact factor: 22.113

9.  Modelling Myc inhibition as a cancer therapy.

Authors:  Laura Soucek; Jonathan Whitfield; Carla P Martins; Andrew J Finch; Daniel J Murphy; Nicole M Sodir; Anthony N Karnezis; Lamorna Brown Swigart; Sergio Nasi; Gerard I Evan
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

10.  miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth.

Authors:  Marija Mihailovich; Michael Bremang; Valeria Spadotto; Daniele Musiani; Elena Vitale; Gabriele Varano; Federico Zambelli; Francesco M Mancuso; David A Cairns; Giulio Pavesi; Stefano Casola; Tiziana Bonaldi
Journal:  Nat Commun       Date:  2015-11-10       Impact factor: 14.919

View more
  31 in total

1.  The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels.

Authors:  Francesca R Dejure; Nadine Royla; Steffi Herold; Jacqueline Kalb; Susanne Walz; Carsten P Ade; Guido Mastrobuoni; Jens T Vanselow; Andreas Schlosser; Elmar Wolf; Stefan Kempa; Martin Eilers
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

Review 2.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

3.  c-MYC mRNA tail tale about glutamine control of transcription.

Authors:  Chi V Dang
Journal:  EMBO J       Date:  2017-05-15       Impact factor: 11.598

4.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.

Authors:  Robert D Leone; Liang Zhao; Judson M Englert; Im-Meng Sun; Min-Hee Oh; Im-Hong Sun; Matthew L Arwood; Ian A Bettencourt; Chirag H Patel; Jiayu Wen; Ada Tam; Richard L Blosser; Eva Prchalova; Jesse Alt; Rana Rais; Barbara S Slusher; Jonathan D Powell
Journal:  Science       Date:  2019-11-07       Impact factor: 47.728

Review 5.  MYC and tumor metabolism: chicken and egg.

Authors:  Francesca R Dejure; Martin Eilers
Journal:  EMBO J       Date:  2017-11-10       Impact factor: 11.598

6.  Localized Inhibition of Protein Phosphatase 1 by NUAK1 Promotes Spliceosome Activity and Reveals a MYC-Sensitive Feedback Control of Transcription.

Authors:  Giacomo Cossa; Isabelle Roeschert; Florian Prinz; Apoorva Baluapuri; Raphael Silveira Vidal; Christina Schülein-Völk; Yun-Chien Chang; Carsten Patrick Ade; Guido Mastrobuoni; Cyrille Girard; Lars Wortmann; Susanne Walz; Reinhard Lührmann; Stefan Kempa; Bernhard Kuster; Elmar Wolf; Dominik Mumberg; Martin Eilers
Journal:  Mol Cell       Date:  2020-01-31       Impact factor: 17.970

7.  Global analysis of RNA-binding proteins identifies a positive feedback loop between LARP1 and MYC that promotes tumorigenesis.

Authors:  Ng Desi; Qing Yun Tong; Velda Teh; Jia Jia Chan; Bin Zhang; Hossein Tabatabaeian; Hui Qing Tan; Katannya Kapeli; Wenhao Jin; Chun You Lim; Zhi Hao Kwok; Hwee Tong Tan; Shi Wang; Bei-En Siew; Kuok-Chung Lee; Choon-Seng Chong; Ker-Kan Tan; Henry Yang; Dennis Kappei; Gene W Yeo; Maxey Ching Ming Chung; Yvonne Tay
Journal:  Cell Mol Life Sci       Date:  2022-02-23       Impact factor: 9.261

8.  Reprogramming of host glutamine metabolism during Chlamydia trachomatis infection and its key role in peptidoglycan synthesis.

Authors:  Karthika Rajeeve; Nadine Vollmuth; Sudha Janaki-Raman; Thomas F Wulff; Apoorva Baluapuri; Francesca R Dejure; Claudia Huber; Julian Fink; Maximilian Schmalhofer; Werner Schmitz; Rajeeve Sivadasan; Martin Eilers; Elmar Wolf; Wolfgang Eisenreich; Almut Schulze; Jürgen Seibel; Thomas Rudel
Journal:  Nat Microbiol       Date:  2020-08-03       Impact factor: 17.745

9.  Adenylosuccinate lyase hydroxylation contributes to triple negative breast cancer via the activation of cMYC.

Authors:  Giada Zurlo; Qing Zhang
Journal:  Mol Cell Oncol       Date:  2020-01-10

10.  CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer.

Authors:  S Denk; S Schmidt; Y Schurr; G Schwarz; F Schote; M Diefenbacher; C Armendariz; F Dejure; M Eilers; Armin Wiegering
Journal:  Int J Colorectal Dis       Date:  2020-10-19       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.